0001745114-22-000004 | 20-F | XBRL Viewer

Personnel expenses

12 Months Ended

Dec. 31, 2021


in CHF thousands	2021	2020	2019
Salaries	(25,909)	(23,525)	(18,868)
Share-based compensation (non-cash effective)	(4,085)	(2,932)	(2,438)
Pension costs	(3,059)	(3,080)	(2,018)
Social security costs	(2,535)	(2,393)	(1,894)
Other personnel expenses	(663)	(1,704)	(2,374)
Total year ended December 31	(36,251)	(33,634)	(27,592)

Full-time equivalents and head count	2021	2020	2019
Average number of full-time equivalents	158.3	142.5	127.1
Full-time equivalents at year end	163.2	145.4	135.2
Headcount at year end	177	159	147

18.1 Pension costs and liabilities


in CHF thousands	2021	2020
Defined benefit pension plans
Actuarial assumptions
Discount rate at January 1	0.20%	0.20%
Discount rate at December 31 (1)	0.40%	0.20%
Future salary increases at December 31	2.00%	2.00%
Mortality tables	BVG2020 GT	BVG2015 GT
Date of last actuarial valuation	31.12.2021	31.12.2020
Reconciliation of the amount recognized in the statement of financial position
Defined benefit obligation at December 31	54,461	54,512
Fair value of plan assets at December 31	47,979	41,089
Net defined benefit liability at December 31 (2)	6,483	13,423
Components of defined benefit cost in profit or loss
Current service cost (employer)	3,097	3,033
Past service cost	(94)	—
Interest expense on defined benefit obligation	114	103
Interest income on plan assets	(86)	(80)
Administrative cost excl. cost for managing plan assets	27	24
Defined benefit cost recognized in profit or loss	3,059	3,080
thereof service cost and administrative cost	3,031	3,057
thereof net interest expense on the net defined benefit liability	28	23
Reconciliation of net defined benefit liability
Net defined benefit liability at January 1	13,423	10,656
Defined benefit cost recognized in profit or loss (3)	3,059	3,080
Remeasurement of net pension liabilities	(8,012)	1,514
Contributions by the employer (3)	(1,987)	(1,827)


Net defined benefit liability at December 31 (2)	6,483	13,423
Reconciliation of defined benefit obligation
Defined benefit obligation at January 1	54,512	48,455
Interest expenses on defined benefit obligation	114	103
Current service cost (employer)	3,097	3,033
Contributions by plan participants	1,246	1,138
Benefits (paid)/deposited	1,067	1,424
Past service cost	(94)	—
Administrative cost (excl. cost for managing plan assets)	27	24
Actuarial (gain)/loss on defined benefit obligation	(5,508)	335
Defined benefit obligation at December 31	54,461	54,512
Reconciliation of amount recognized in OCI
Actuarial (gain) / loss on changes in financial assumptions	(2,303)	—
Actuarial (gain) / loss on changes in demographic assumptions	(2,432)	—
Actuarial (gain) / loss arising from experience adjustments	(773)	335
Actuarial (gain)/loss on defined benefit obligation	(5,508)	335
Return on plan assets excluding interest income	(2,504)	1,179
Remeasurement of net pension liabilities	(8,012)	1,514
Reconciliation of fair value of plan assets
Fair value of plan assets at January 1	41,089	37,799
Interest income on plan assets	86	80
Contributions by the employer	1,987	1,827
Contributions by plan participants	1,246	1,138
Benefits (paid)/deposited	1,067	1,424
Return on plan assets excl. interest income	2,504	(1,179)
Fair value of plan assets at December 31	47,979	41,089
Best estimate of contributions of next year
Contributions by the employer	2,060	1,834
Plan asset classes
Cash and cash equivalents	9,581	8,118
Equity instruments	20,246	16,791
Debt instruments (e.g. bonds)	6,130	5,671
Real estate funds	1,612	1,075
Others	1,547	1,483
Total plan assets at fair value (quoted market price)	39,116	33,138
Others	8,862	7,951
Total plan assets at fair value (non-quoted market price)	8,862	7,951
Total plan assets at fair value at December 31	47,979	41,089
thereof entity's own transferable financial instruments	—	—
thereof property occupied or other assets used by the entity	—	—
Sensitivity (4)
Defined benefit obligation at December 31 with discount rate -0.25%	57,066	57,383
Defined benefit obligation at December 31 with discount rate +0.25%	52,054	51,871
Defined benefit obligation at December 31 with interest rate on retirement savings capital -0.25%	53,576	53,598


Defined benefit obligation at December 31 with interest rate on retirement savings capital +0.25%	55,373	55,454
Defined benefit obligation at December 31 with salary increases -0.25%	53,993	54,033
Defined benefit obligation at December 31 with salary increases +0.25%	54,947	54,999
Defined benefit obligation at December 31 with life expectancy +1 year	55,283	55,417
Defined benefit obligation at December 31 with life expectancy -1 year	53,569	53,611
Maturity profile of defined benefit obligation
Weighted average duration of defined obligation in years at December 31	18.5	20.2
Weighted average duration of defined obligation in years at December 31 for active members	18.3	20.2
Weighted average duration of defined obligation in years at December 31 for pensioners	19.6	20.3

(1) Discount rates are based on industry benchmarks related to benefits with a 20 year duration

(2) In liabilities for employee benefits, as presented in the consolidated statement of financial position included are also TCHF 257 (2020: TCHF 255; 2019: TCHF 240) for accrued sabbatical cost.

(3) The sum of these two positions represent the non-cash effective pension costs recognized in the profit and loss section of the consolidated statement of comprehensive loss of which TCHF 837 are research and development costs (2020: TCHF 1,039; 2019: TCHF 358) and TCHF 235 are selling, general and administrative costs (2020: TCHF 214; 2019: TCHF 104).

(4) For the most important parameters which influence the pension obligation of the Company a sensitivity analysis was performed. The discount rate and the assumption for salary increases were modified by a certain percentage value. Sensitivity on mortality was calculated by changing the mortality with a constant factor for all age groups. With this procedure we could change the longevity for most of the age categories by one year longer or shorter than the baseline value.

The table below presents the amounts that are reflected in the statement of comprehensive loss for the periods indicated:


in CHF thousands	2021	2020	2019

Components of defined benefit cost in profit or loss
Current service cost (employer)	3,097	3,033	2,053
Past service cost	(94)	—	(105)
Interest expense on defined benefit obligation	114	103	356
Interest income on plan assets	(86)	(80)	(304)
Administrative cost excl. cost for managing plan assets	27	24	18
Defined benefit cost recognized in profit or loss	3,059	3,080	2,018
thereof service cost and administrative cost	3,031	3,057	1,966
thereof net interest expense on the net defined benefit liability	28	23	52

Reconciliation of amount recognized in OCI
Actuarial (gain) / loss on changes in financial assumptions	(2,303)	—	4,774
Actuarial (gain) / loss on changes in demographic assumptions	(2,432)	—	—
Actuarial (gain) / loss arising from experience adjustments	(773)	335	963
Actuarial (gain)/loss on defined benefit obligation	(5,508)	335	5,737
Return on plan assets excluding interest income	(2,504)	1,179	(1,026)
Remeasurement of net pension liabilities	(8,012)	1,514	4,711

Best estimate of contributions of next year
Contributions by the employer	2,060	1,834	1,724

18.2 Share-based compensation

18.2.1 Employee Share Option Plans (“ESOP”)

1. ESOP 2009 established in December 2009

2. ESOP 2014 established in July 2014

An ESOP is an incentive tool that fosters the entrepreneurial spirit and performance by way of financial participation in the Group’s long term success. It gives employees, members of the Board of Directors and selected advisors a beneficial opportunity to purchase shares of the Company. Each option entitles its holder to purchase one share of the Company at a pre-defined exercise price. The number of options granted to each participant was determined by the Board of Directors based on a participant’s position and level of responsibility. The options generally vest quarterly over four years, with vesting of 25% after one year. At the end of the option term, unexercised options expire without value. The expenses are recognized pro rata as per the graded vesting schedule starting generally from grant date until vesting date.

As of December 31, 2021, an aggregate of 318,902 options were outstanding under the ESOP 2009 and ESOP 2014. All these options are fully vested at the reporting date.

As of December 31, 2020, an aggregate of 382,059 options were outstanding under the ESOP 2009 and ESOP 2014.

Since the initial public offering of the Company on the SIX Swiss Exchange on November 5, 2014, no further option grants have been made under any of these two share option plans.

18.2.2 Long Term Incentive (“LTI”) Plans: Restricted Share Units ("RSU'') and Performance Share Units ("PSU")

•LTI plans 2017 established in March 2017

•LTI plans 2018 established in March 2018

•LTI plans 2019 established in March 2019

•LTI plans 2020 established in March 2020

•LTI plans 2021 established in March 2021

Under the LTI plans, members of the Board of Directors are eligible to be granted RSUs, whereas members of the Management Board and other employees are eligible to be granted PSUs.

RSUs are contingent rights to receive a certain number of shares of the Company at the end of a three-year blocking period. The number of RSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each RSU as at the grant date. In certain circumstances, including a change of control, a full or partial accelerated vesting of the RSUs may occur. RSUs vest over a one-year period from date of grant.

PSUs are contingent rights to receive a variable number of shares of the Company. PSUs granted under the PSU Plan 2021 for employees (except for members of the Management Board) will vest in three tranches of one third each. The first tranche of the PSUs shall vest on the first anniversary of the grant date, the second tranche on the second anniversary of the grant date and the third tranche on the third anniversary of the grant date. Under the PSU Plan 2021 for the members of the Management Board, the vesting schedule is at the end of a three year cliff-vesting period. PSUs granted to all employees under PSU plans of prior years will continue to vest at the end of a three-year cliff-vesting period.

The number of PSUs per plan participant is a function of the approved CHF amount per position divided by the fair value of each PSU as of the grant date. While the PSUs are designed to let the beneficiaries participate in the long-term share price development, the number of shares to be earned in relation to a PSU also depends on the achievement of pre-defined corporate goals for the respective year. Accordingly, the number of shares to be issued based on the PSUs can be between zero and 120% of the number of PSUs granted. Even after the determination of goal achievement, participants may lose their entitlements in full or in part depending on certain conditions relating to their employment. In certain circumstances, including a change of control, a full or partial accelerated vesting of the PSUs may occur.

The LTI plans are issued annually, which allows the Board of Directors to review the terms and determine the targets on an annual basis. Employees generally receive the grants on April 1 of each calendar year, or for new employees on the first day of the calendar quarter after the start of their employment. Members of the Management Board and the Board of Directors receive the annual grants after the approval of the ordinary shareholders’ meeting.

As of December 31, 2021,547,485 PSUs and 95,635 RSUs were outstanding. As of December 31, 2020, 445,198 PSUs and 87,906 RSUs were outstanding.

18.2.3 Conditions attached to and measurement of fair values of equity-settled share-based payment arrangements

The following table provides the conditions as well as the inputs used in the measurement of the fair values at grant dates:


RSU/PSU, conditions and assumptions	2021	2020
Nature of arrangement	Grant of PSU/RSU	Grant of PSU/RSU
Grant date RSU	April 21, 2021	April 29, 2020
Grant dates PSU	Jan 1 - Oct 1	Jan 1 - Oct 1
Number of RSU granted	29,519	33,467
Number of PSU granted	230,536	267,657
Weighted average exercise price (CHF)	0.10	0.10
Share price (CHF)	17.90 - 23.25	14.50 - 21.50
Full contractual life for RSU (years)	3.00	3.00
Full contractual life for PSU (years)	2.25 - 3.00	2.25 - 3.00
Vesting period for RSU (years)	1.00	1.00
Vesting period for PSU (years), Management Board	2.25 - 3.00	n.a.
Vesting period for PSU (years), employees excluding Management Board	2.25 - 3.00 (pro-rata annual vesting)	n.a.
Vesting period for PSU (years), all awards	n.a.	2.25 - 3.00
Settlement	Common Shares	Common Shares
Expected volatility on Common shares	58.57 - 61.69	42.73 - 56.26
Risk-free interest rate p. a. (%) / CHF LIBOR / Common shares	(0.58) - (0.61)	(0.42) - (0.60)
Expected volatility on NBI	26.21 - 27.01	21.20 - 25.70
Risk-free interest rate p. a. (%) / USD LIBOR / NBI	0.24 - 0.34	0.36 - 2.00
Expected volatility on SPI	15.96 - 16.15	11.19 - 15.79
Risk-free interest rate p. a. (%) / CHF LIBOR / SPI	(0.58) - (0.61)	(0.42) - (0.60)
Expected dividend (CHF)	—	—
Weighted average fair value of rights granted (CHF)	24.56	20.18
Latest expiry date	Sep 30, 2024	Sep 30, 2023
Valuation model	Monte Carlo	Monte Carlo

Additional comments:

•Expected volatility: Historical share prices of the Company have been used.

•The indices, Nasdaq Biotechnology Index ('NBI") and Swiss performance Index ("SPI") are used as inputs in determining the fair values for the 2020 and 2021 PSU Plans

The movements in the number of all issued RSUs, PSUs and share options are as follows:


Share option / PSU / RSU movements	Total (numbers)	Weighted average exercise price (CHF)	Options (numbers)	Weighted average exercise price (CHF)	PSU/RSU (numbers)	Weighted average exercise price (CHF)
Balance outstanding at December 31, 2019	1,005,255	3.32	560,250	5.87	445,005	0.10
Granted	301,124	0.10	—	—	301,124	0.10
(Performance adjustment) (1)	(27,956)	0.10	—	—	(27,956)	0.10
(Forfeited) (2)	(84,679)	0.10	—	—	(84,679)	0.10
(Expired)	—	—	—	—	—	—
(Exercised) (3)	(278,581)	3.05	(178,191)	4.70	(100,390)	0.10
Balance outstanding at December 31, 2020	915,163	2.74	382,059	6.42	533,104	0.10
Granted	260,055	0.10	—	—	260,055	0.10
(Performance adjustment) (1)	(1,022)	0.10	—	—	(1,022)	0.10
(Forfeited) (2)	(66,518)	0.10	—	—	(66,518)	0.10
(Expired)	—	—	—	—	—	—
(Exercised) (3)	(145,656)	1.85	(63,157)	4.14	(82,499)	0.10
Balance outstanding at December 31, 2021	962,022	2.35	318,902	6.87	643,120	0.10

(1) Performance adjustments indicate forfeitures due to non-market performance conditions not achieved

(2) Forfeited due to service conditions not fulfilled

(3) The weighted average share prices at the dates of exercising during the year ended 2021 amounted to CHF 19.87 (2020: CHF 19.73)

The following table applies to all share options, PSUs and RSUs outstanding at December 31, 2021:


Exercise price CHF	Options / PSU/RSU (number)	Remaining life (years)	Thereof exercisable options
Options
2.31	1,160	0.7	1,160
6.05	2,815	1.0	2,815
6.06	15,450	2.4	15,450
6.94	299,477	2.7	299,477
PSU/RSU
0.10	643,120	1.2
Total	962,022		318,902

The following table applies to all share options, PSUs and RSUs outstanding at December 31, 2020:


Exercise price CHF	Options / PSU/RSU (number)	Remaining life (years)	Thereof exercisable options
Options
2.31	38,917	0.6	38,917
6.05	2,815	2.0	2,815
6.06	17,942	3.3	17,942
6.94	322,385	3.7	322,385
PSU/RSU
0.10	533,104	1.6	—
Total	915,163		382,059

The non-cash costs for share-based payments recognized in the statement of comprehensive loss can be attributed to the Group’s two functions as follows:


in CHF thousands	2021	2020	2019
Research and development	2,208	1,573	1,192
Selling, general and administrative	1,877	1,359	1,246
Total year ended December 31	4,085	2,932	2,438

Summary of significant accounting policies (Policies)	12 Months Ended
Dec. 31, 2021
Disclosure Of Significant Accounting Policies [Abstract]
Basis of consolidation	Basis of consolidation (i) Subsidiaries Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. (ii) Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.

General information (Details) - $ / shares		12 Months Ended
Jun. 15, 2021	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of General Information [Abstract]
Initial Public Offering, number of shares issued (in shares)	3,000,000	3,145,656	7,545,800
Initial Public Offering, price per share (in USD per share)	$ 21.25

Label

Element

Value

Vesting Requirements For Share-Based Payment Arrangement, Blocking Period

moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod

3 years

Right-Of-Use Assets, Lease Agreement, Extension Period

moln_RightOfUseAssetsLeaseAgreementExtensionPeriod

5 years

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

SFr 0

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

18,584,000

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

18,584,000

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

20,000,000

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

7,000,000

Increase Through Additions, Contract Liabilities

moln_IncreaseThroughAdditionsContractLiabilities

27,000,000

Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost

moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost

3,045,000

Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost

moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost

2,612,000

Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost

moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost

1,549,000

Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost

moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost

2,113,000

Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost

moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost

1,573,000

Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost

moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost

SFr 1,351,000

Disclosure Of Detailed Information About Trade And Other Payables [Table Text Block]

moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock


in CHF thousands	2021	2020
Trade payables	4,862	2,800
Social security	1,672	1,715
Value added tax	855	1,310
Balance at December 31	7,389	5,825

Trade payables are denominated in the following currencies:


in CHF thousands	2021	2020
CHF	1,464	556
EUR	3,250	2,043
USD	118	17
GBP	29	184
Balance at December 31	4,862	2,800

Royalties And License Fees Expense

moln_RoyaltiesAndLicenseFeesExpense

SFr 60,000

Royalties And License Fees Expense

moln_RoyaltiesAndLicenseFeesExpense

562,000

Royalties And License Fees Expense

moln_RoyaltiesAndLicenseFeesExpense

50,000

Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities

moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities

88,876,000

Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities

moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities

73,397,000

Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities

moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities

75,998,000

Potential Future Milestone Payments, Initiation And Completion Of Clinical Trials

moln_PotentialFutureMilestonePaymentsInitiationAndCompletionOfClinicalTrials

SFr 2,500,000

Disclosure Of Royalties And License Fees [Text Block]

moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock

Royalties and license fees

Until October 2021, the Group held an exclusive perpetual license from the University of Zurich on patent applications and patents relating to the DARPin base technology. The Group terminated the applicable license agreement with effect as of October 2021 as the main patent under this agreement expired in September 2021.

Under this license agreement, the Group was required to pay the University of Zurich flat royalties of a low single digit percentage on net sales of licensed products, which vary based on the field in which the licensed product is commercialized. In addition, the Group was obligated to pay the University of Zurich a percentage of license fee revenues it receives from sublicensing its rights to third parties in five tiers, ranging from the low single digits to the low teens, depending on the total amount of payments received for the particular sublicense granted.

Finally, the Group was also obligated to pay the University of Zurich a percentage of the royalty payments it receives from sublicensees in three tiers based on their net sales of licensed products and the applicable field in which the licensed product is sold, ranging from the low single digits to the mid teens. The minimum amount the Group was required to pay is CHF 60,000 per annum (including CHF 10,000 for another separate license). For the years 2021, 2020 and 2019 the minimum amounts of CHF 50,000 were payable. Royalties to the University of Zurich were due annually based on a full calendar year and payable until the end of February in the following calendar year.

In May 2020, the Group entered into a Research collaboration agreement with the University of Utrecht regarding the development of the Group's COVID-19 program. Under this agreement, the Group paid a fee of CHF 250,000 to the University of Utrecht in December 2020. An additional fee of CHF 250,000 is accrued as per December 2021

and payable under this agreement. Upon Novartis exercising their option under the Option and equity rights agreement, the University of Utrecht will be due a further CHF 1.0 million (please also see note 26).

Second Reservation Right, Maximum Amount Of Additional Doses Reserved

moln_SecondReservationRightMaximumAmountOfAdditionalDosesReserved

3,000,000

Second Reservation Right, Maximum Amount Of Additional Doses Reserved

moln_SecondReservationRightMaximumAmountOfAdditionalDosesReserved

1,300,000

Royalties, Minimum Annual Amount, Total

moln_RoyaltiesMinimumAnnualAmountTotal

SFr 60,000

Potential Future Milestone Payments, Initiation And Completion Of Clinical Trials, Number Of Milestone Payments

moln_PotentialFutureMilestonePaymentsInitiationAndCompletionOfClinicalTrialsNumberOfMilestonePayments

Royalties, Minimum Annual Amount, Separate License

moln_RoyaltiesMinimumAnnualAmountSeparateLicense

SFr 10,000

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

19,904,000

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

96,000

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

19,904,000

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

Decrease Through Offset Of Costs, Contract Liabilities

moln_DecreaseThroughOffsetOfCostsContractLiabilities

SFr 96,000

Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories

moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories

1 year

Post-Employment Benefit Expense, Non-Cash Effective Pension Cost

moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost

SFr 837,000

Post-Employment Benefit Expense, Non-Cash Effective Pension Cost

moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost

1,039,000

Post-Employment Benefit Expense, Non-Cash Effective Pension Cost

moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost

358,000

Post-Employment Benefit Expense, Non-Cash Effective Pension Cost

moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost

235,000

Post-Employment Benefit Expense, Non-Cash Effective Pension Cost

moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost

214,000

Post-Employment Benefit Expense, Non-Cash Effective Pension Cost

moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost

SFr 104,000

Extended Period Of Reservation Agreement

moln_ExtendedPeriodOfReservationAgreement

6 months

License Fees Expense

moln_LicenseFeesExpense

SFr 250,000

Disclosure Of Prepaid Expenses And Accrued Income [Text Block]

moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock

Prepaid expenses and accrued income


in CHF thousands	2021	2020
Prepayments	5,652	1,252
Accrued income	76	2
Balance at December 31	5,728	1,254

The increase in prepayments relates mainly to payments for director and officer insurance following our June 2021 US equity listing.

Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Percentage

moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPercentage

25.00%

Current Accrued Project Costs And Royalties

moln_CurrentAccruedProjectCostsAndRoyalties

SFr 3,410,000

Current Accrued Project Costs And Royalties

moln_CurrentAccruedProjectCostsAndRoyalties

1,972,000

Current Accrued Project Costs And Royalties

moln_CurrentAccruedProjectCostsAndRoyalties

SFr 250,000

Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period

moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod

3 years

Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period

moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod

3 years

Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period

moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod

1 year

Disclosure Of Current And Non-Current Contract Liabilities [Table Text Block]

moln_DisclosureOfCurrentAndNonCurrentContractLiabilitiesTableTextBlock


in CHF thousands	Current	Non-current	Contract liability
Amgen	9,653	—	9,653
Novartis	11,659	6,925	18,584
FOPH	7,000	—	7,000
Balance at December 31, 2021	28,312	6,925	35,237


in CHF thousands	Current	Non-current	Contract liability
Amgen	16,044	2,939	18,983
Novartis	19,904	—	19,904
FOPH	7,000	—	7,000
Balance at December 31, 2020	42,948	2,939	45,887

Royalty, Payable

moln_RoyaltyPayable

SFr 1,000,000

Number Of Share Option Plans

moln_NumberOfShareOptionPlans

Upfront Payment Received

moln_UpfrontPaymentReceived

SFr 20,000,000

Upfront Payment Received

moln_UpfrontPaymentReceived

SFr 50,000,000

Upfront Payment Received

moln_UpfrontPaymentReceived

SFr 18,600,000

Upfront Payment Received

moln_UpfrontPaymentReceived

SFr 20,000,000

Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches

moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches

Second Reservation Right, Percentage Of Additional Planned Total Production

moln_SecondReservationRightPercentageOfAdditionalPlannedTotalProduction

5.00%

Number Of Other Equity Instruments Issued In Share-Based Payment Arrangement, In Percentage Of Number Granted

moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted

0.00%

Number Of Other Equity Instruments Issued In Share-Based Payment Arrangement, In Percentage Of Number Granted

moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted

120.00%

Royalty Income, Percentage

moln_RoyaltyIncomePercentage

22.00%

Accrued Sabbatical Cost

moln_AccruedSabbaticalCost

SFr 257,000

Accrued Sabbatical Cost

moln_AccruedSabbaticalCost

255,000

Accrued Sabbatical Cost

moln_AccruedSabbaticalCost

240,000

Potential Future Milestone Payments, Exercice Of Option For Exclusive License

moln_PotentialFutureMilestonePaymentsExerciceOfOptionForExclusiveLicense

SFr 150,000,000

Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table Text Block]

moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock


in CHF thousands	2021	2020
Cash at bank in CHF	44,621	96,576
Cash at bank in EUR	20,313	6,365
Cash at bank in USD	5,821	29,776
Cash at bank in GBP	1,058	1,004
Total cash at bank at December 31	71,813	133,721

Short-term time deposits in CHF	20,000	40,000
Short-term time deposits in USD	41,000	—
Total short-term deposits at December 31	61,000	40,000

Research Consumables And External Research And Development Expense

moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense

SFr 26,342,000

Research Consumables And External Research And Development Expense

moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense

26,599,000

Research Consumables And External Research And Development Expense

moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense

SFr 20,314,000

Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income [Table Text Block]

moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock


in CHF thousands	2021	2020
Prepayments	5,652	1,252
Accrued income	76	2
Balance at December 31	5,728	1,254

First Reservation Right, Number Of Initial Doses Reserved

moln_FirstReservationRightNumberOfInitialDosesReserved

200,000

Adjustments For Decrease (Increase) In Prepaid Expenses And Accrued Income

moln_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndAccruedIncome

SFr (4,445,000)

Adjustments For Decrease (Increase) In Prepaid Expenses And Accrued Income

moln_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndAccruedIncome

1,040,000

Adjustments For Decrease (Increase) In Prepaid Expenses And Accrued Income

moln_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndAccruedIncome

SFr 453,000

Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits [Text Block]

moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock

Cash, cash equivalents and short-term time deposits


in CHF thousands	2021	2020
Cash at bank in CHF	44,621	96,576
Cash at bank in EUR	20,313	6,365
Cash at bank in USD	5,821	29,776
Cash at bank in GBP	1,058	1,004
Total cash at bank at December 31	71,813	133,721

Short-term time deposits in CHF	20,000	40,000
Short-term time deposits in USD	41,000	—
Total short-term deposits at December 31	61,000	40,000

The short-term time deposits in CHF at December 31, 2021 contain one position with one major Swiss bank and the short-term time deposits denominated in USD contain three positions with two major Swiss banks. The short-term time deposits in CHF at December 31, 2020 contain three positions with two major Swiss banks. Please also refer to note 25.

Upfront Payment, Amount Utilized During Period

moln_UpfrontPaymentAmountUtilizedDuringPeriod

SFr 20,000,000

Number Of Reservation Rights

moln_NumberOfReservationRights

Industry Benchmark, Discount Rates, Period

moln_IndustryBenchmarkDiscountRatesPeriod

20 years

Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory [Table Text Block]

moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock


in CHF thousands	2021	2020
Accrued project costs and royalties	3,410	1,972
Accrued payroll and bonuses	6,002	4,967
Other	563	779
Balance at December 31	9,975	7,718

Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans

moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans

SFr 5,508,000

Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans

moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans

(335,000)

Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans

moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans

(5,737,000)

Service Cost And Administrative Cost, Defined Benefit Plans

moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans

3,031,000

Service Cost And Administrative Cost, Defined Benefit Plans

moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans

3,057,000

Service Cost And Administrative Cost, Defined Benefit Plans

moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans

1,966,000

Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities

moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities

67,876,000

Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities

moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities

52,765,000

Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities

moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities

56,630,000

Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets

moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets

Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets

moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets

Adjustment For Exchange Gains (Losses) On Working Capital Positions

moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions

144,000

Adjustment For Exchange Gains (Losses) On Working Capital Positions

moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions

(6,000)

Adjustment For Exchange Gains (Losses) On Working Capital Positions

moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions

SFr (604,000)

Number Of Indicators, Clinical Development Costs

moln_NumberOfIndicatorsClinicalDevelopmentCosts

Other Research And Development Expense

moln_OtherResearchAndDevelopmentExpense

SFr 259,000

Other Research And Development Expense

moln_OtherResearchAndDevelopmentExpense

169,000

Other Research And Development Expense

moln_OtherResearchAndDevelopmentExpense

191,000

Adjustments For Increase (Decrease) In Accrued Expenses

moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses

2,290,000

Adjustments For Increase (Decrease) In Accrued Expenses

moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses

1,037,000

Adjustments For Increase (Decrease) In Accrued Expenses

moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses

217,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

52,054,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

51,871,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

55,373,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

55,454,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

54,947,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

54,999,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

53,569,000

Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption

53,611,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

57,066,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

57,383,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

53,576,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

53,598,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

53,993,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

54,033,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

55,283,000

Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption

moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

SFr 55,417,000

Disclosure Of Detailed Information About Financial Expense [Table Text Block]

moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock

Financial expense


in CHF thousands	2021	2020	2019
Net foreign exchange loss	—	(4,512)	(1,110)
Negative interest on financial assets held at amortized costs	(495)	(271)	(64)
Interest expense on leases	(53)	(24)	(27)
Other financial expenses	(8)	(9)	(9)
Total year ended December 31	(556)	(4,816)	(1,210)

Reasonably Possible Decrease In Actuarial Assumptions, Period

moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod

1 year

Reasonably Possible Decrease In Actuarial Assumptions, Period

moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod

1 year

Maximum Amount Of Share Capital Increase Authorized

moln_MaximumAmountOfShareCapitalIncreaseAuthorized

SFr 428,675

Maximum Amount Of Share Capital Increase Authorized

moln_MaximumAmountOfShareCapitalIncreaseAuthorized

SFr 728,675

Maximum Amount Of Share Capital Increase Authorized, Number Of Shares

moln_MaximumAmountOfShareCapitalIncreaseAuthorizedNumberOfShares

4,286,750

Lease, Cost Recognised In Profit Or Loss

moln_LeaseCostRecognisedInProfitOrLoss

SFr 1,253,000

Lease, Cost Recognised In Profit Or Loss

moln_LeaseCostRecognisedInProfitOrLoss

1,280,000

Lease, Cost Recognised In Profit Or Loss

moln_LeaseCostRecognisedInProfitOrLoss

SFr 1,276,000

Potential Future Milestone Payments

moln_PotentialFutureMilestonePayments

SFr 560,000,000

Potential Future Milestone Payments

moln_PotentialFutureMilestonePayments

SFr 497,000,000

Increase (Decrease) In Authorized Share Capital

moln_IncreaseDecreaseInAuthorizedShareCapital

SFr (300,000)

Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share

moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare

835,422

Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share

moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare

794,377

Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share

moln_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare

814,855

Negative Interest Revenue For Financial Assets Measured At Amortised Cost

moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost

SFr 495,000

Negative Interest Revenue For Financial Assets Measured At Amortised Cost

moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost

271,000

Negative Interest Revenue For Financial Assets Measured At Amortised Cost

moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost

SFr 64,000

Reasonably Possible Increase In Actuarial Assumptions, Period

moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod

1 year

Reasonably Possible Increase In Actuarial Assumptions, Period

moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod

1 year

Preemptive Rights, Over-Allotment Option, Maximum Percentage Of Total Number Of Shares In A Placement

moln_PreemptiveRightsOverAllotmentOptionMaximumPercentageOfTotalNumberOfSharesInAPlacement

20.00%

Preemptive Rights, Shareholders, Percentage Of Share Capital Registered Accumulated

moln_PreemptiveRightsShareholdersPercentageOfShareCapitalRegisteredAccumulated

15.00%

Authorized Share Capital, Employee Participation

moln_AuthorizedShareCapitalEmployeeParticipation

SFr 161,502

Authorized Share Capital, Employee Participation

moln_AuthorizedShareCapitalEmployeeParticipation

SFr 176,068

Number Of Shares Authorized, Employee Participation

moln_NumberOfSharesAuthorizedEmployeeParticipation

1,615,021

Intellectual Property Expense

moln_IntellectualPropertyExpense

SFr 636,000

Intellectual Property Expense

moln_IntellectualPropertyExpense

492,000

Intellectual Property Expense

moln_IntellectualPropertyExpense

568,000

Increase (Decrease) In Authorized Share Capital, Employee Participation

moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation

(14,566)

Authorized Share Capital, Financing Transactions

moln_AuthorizedShareCapitalFinancingTransactions

SFr 226,087

Number Of Shares Authorized, Financing Transactions

moln_NumberOfSharesAuthorizedFinancingTransactions

2,260,870

Disclosure Of Movement Of Lease Liabilities [Table Text Block]

moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock

Set out below are the carrying amounts of the lease liabilities and the movements during the period:


in CHF thousands	2021	2020
as at January 1,	7,218	2,545
Additions / new leases	—	—
Remeasurements (1)	—	5,924
Recognition of interest on lease liabilities	53	24
Payments	(1,232)	(1,275)
Balance as at December 31,	6,039	7,218

Current	1,189	1,179
Non-current	4,850	6,039
Balance as at December 31,	6,039	7,218

(1) The remeasurement consists of a net reduction of TCHF 60 (related to the return of number of parking spaces) and an increase of TCHF 5,984 related to the extension of the lease for another 5 years until December 31, 2026

Disclosure Of Detailed Information About Financial Income [Table Text Block]

moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock

Financial income


in CHF thousands	2021	2020	2019
Interest income on financial assets held at amortized costs	99	367	1,599
Net foreign exchange gain	92	—	—
Total year ended December 31	191	367	1,599

Disclosure Of Detailed Information About Trade And Other Receivables [Table Text Block]

moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock


in CHF thousands	2021	2020
Trade receivables	23,710	159
Value added tax	1,770	1,376
Withholding tax	24	199
Other receivables	146	1,103
Balance at December 31	25,650	2,837

Trade receivables are denominated in the following currencies:


in CHF thousands	2021	2020
CHF	958	159
EUR	3,127	—
USD	19,625	—
Balance at December 31	23,710	159

Number Of Votes Per Share

moln_NumberOfVotesPerShare

Minimum [Member]

Lease, Term Of Contract

moln_LeaseTermOfContract

2 years

Maximum [Member]

Lease, Term Of Contract

moln_LeaseTermOfContract

10 years

Lease, Extension Or Termination Option, Period

moln_LeaseExtensionOrTerminationOptionPeriod

1 year

Mark N. Lampert (Biotechnology Value Funds) [Member]

Shareholders, Number Of Shares Held In The Company

moln_ShareholdersNumberOfSharesHeldInTheCompany

3,926,282

Shareholders, Number Of Shares Held In The Company

moln_ShareholdersNumberOfSharesHeldInTheCompany

4,526,282

Shareholders, Percentage Of Voting Rights In The Company

moln_ShareholdersPercentageOfVotingRightsInTheCompany

12.21%

Shareholders, Percentage Of Voting Rights In The Company

moln_ShareholdersPercentageOfVotingRightsInTheCompany

14.08%

United States of America, Dollars

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

SFr 6,633,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

2,976,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

6,642,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

234,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

149,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

SFr 333,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

SFr 6,633,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

2,976,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

6,642,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

234,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

149,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

SFr 333,000

Number Of Short-Term Time Deposit Positions

moln_NumberOfShortTermTimeDepositPositions

Number Of Banks Where Deposits Are Held

moln_NumberOfBanksWhereDepositsAreHeld

Euro Member Countries, Euro

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

SFr 2,019,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

432,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

1,171,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

102,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

32,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

SFr 64,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

10.00%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

SFr 2,019,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

432,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

1,171,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

102,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

32,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

SFr 64,000

Switzerland, Francs

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

SFr 323,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

683,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax

SFr 57,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent

0.50%

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

SFr 323,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

683,000

Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax

moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax

SFr 57,000

Number Of Short-Term Time Deposit Positions

moln_NumberOfShortTermTimeDepositPositions

Number Of Short-Term Time Deposit Positions

moln_NumberOfShortTermTimeDepositPositions

Number Of Banks Where Deposits Are Held

moln_NumberOfBanksWhereDepositsAreHeld

Number Of Banks Where Deposits Are Held

moln_NumberOfBanksWhereDepositsAreHeld

Novartis [Member]

Shareholders, Share Capital Acquired In The Company

moln_ShareholdersShareCapitalAcquiredInTheCompany

SFr 40,000,000

Shareholders, Share Capital Acquired In The Company, Per Share

moln_ShareholdersShareCapitalAcquiredInTheCompanyPerShare

SFr 23

Shareholders, Percentage Of Share Capital In The Company

moln_ShareholdersPercentageOfShareCapitalInTheCompany

5.40%

Summary of significant accounting policies - Segment Reporting (Details)	12 Months Ended
	Dec. 31, 2021 segment
Disclosure Of Significant Accounting Policies [Abstract]
Number of operating segments	1

Summary of significant accounting policies - Employee Benefits (Details)	12 Months Ended
	Dec. 31, 2021 CHF (SFr) employee	Dec. 31, 2020 CHF (SFr) employee
Disclosure Of Detailed Information About Employee Benefits [Line Items]
Defined benefit plan, employer contribution	70.00%
Defined benefit plan, employee contribution	30.00%
Salary level, minimum threshold \| SFr	SFr 180,000	SFr 150,000
Salary level, minimum threshold, working quota	100.00%
Number of employees that participated	32	29
Number of eligible employees	32	31
Percentage of VSAO contributions in total company's defined benefit plans	90.00%

Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details) - SFr / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]
Share price (in CHF per share)	SFr 23.25	SFr 21.50
Full contractual life for RSU and PSU	3 years	3 years
Vesting period	3 years	3 years
Expected volatility on Common shares	61.69%	56.26%
Risk free interest rate, common shares	(0.61%)	(0.60%)
Expected volatility on NBI	27.01%	25.70%
Risk free interest rate, NBI	0.34%	2.00%
Expected volatility on SPI	16.15%	15.79%
Risk free interest rate, SPI	(0.61%)	(0.60%)
Expected dividend	SFr 0	SFr 0
Weighted average fair value of rights granted (in CHF per shares)	SFr 24.56	SFr 20.18

Personnel expenses - Disclosure of Movements in the Number of All Isues RSUs, PSUs and Share Options (Details)	12 Months Ended
	Dec. 31, 2021 shares SFr / shares	Dec. 31, 2020 shares SFr / shares
Personnel Expenses [Abstract]
Number of instruments outstanding, beginning of period (in shares) \| shares	915,163	1,005,255
Number of instruments forfeited, performance adjustment (in shares) \| shares	(1,022)	(27,956)
Number of instruments forfeited (in shares) \| shares	(66,518)	(84,679)
Number of instruments expired (in shares) \| shares	0	0
Number of instruments exercised (in shares) \| shares	(145,656)	(278,581)
Number of instruments outstanding, end of period (in shares) \| shares	962,022	915,163
Weighted average exercise price of instruments outstanding at beginning of period (in CHF per share)	SFr 2.74	SFr 3.32
Weighted average exercise price of instruments granted (in CHF per share)	0.10	0.10
Weighted average exercise price of instruments forfeited, performance adjustment (in CHF per share)	0.10	0.10
Weighted average exercise price of instruments forfeited (in CHF per share)	0.10	0.10
Weighted average exercise price of instruments expired (in CHF per share)	0	0
Weighted average exercise price of instruments exercised (in CHF per share)	1.85	3.05
Weighted average exercise price of instruments outstanding at end of period (in CHF per share)	SFr 2.35	SFr 2.74
Number of share options forfeited, performance adjustment (in shares) \| shares	0	0
Weighted average exercise price of share options forfeited, performance adjustment (in CHF per share)	SFr 0	SFr 0
Number of PSU and RSU forfeited, performance adjustment (in shares) \| shares	(1,022)	(27,956)
Weighted average exercise price of PSU and RSU forfeited, performance adjustment (in CHF per share)	SFr 0.10	SFr 0.10
Weighted average share price, at date of exercise (in CHF per share)	SFr 19.87	SFr 19.73

Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)	12 Months Ended
	Dec. 31, 2021 shares SFr / shares	Dec. 31, 2020 shares SFr / shares	Dec. 31, 2019 shares
Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]
Exercise price of outstanding PSUs and RSUs (in CHF per share) \| SFr / shares	SFr 0.1	SFr 0.1
Weighted average remaining contractual life of outstanding PSUs and RSUs	1 year 2 months 12 days	1 year 7 months 6 days
Number of instruments outstanding (in shares)	962,022	915,163	1,005,255
Number of instruments exercisable (in shares	318,902	382,059

Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details) - employee	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Personnel Expenses [Abstract]
Average number of full-time equivalents	158.3	142.5	127.1
Full-time equivalents at year end	163.2	145.4	135.2

Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details) - CHF (SFr) SFr in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]
Tax loss carryforwards	SFr 0	SFr (157,900)

Financial risk management - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021 bank
Financial Risk Management [Abstract]
Number of different Swiss banks	4